Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term immune response after pneumococcal vaccination in CLL and effect of revaccination
2018-003377-97Phase 3Completed
- Sponsor
- Swedish CLL Group
- Start
- Nov 2018
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in pneumococcal disease comparing Prior PCV13 arm with Prior PPSV23 arm (2 arms). Primary endpoints: Long-term immune response 3–5 years after initial pneumococcal vaccination and Prevalence of nasopharyngeal pneumococcal colonization. Started Nov 2018; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2018-003377-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003377-97.